Clinical Trial Details

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (TRIPLE-SWITCH)

IRB Protocol Number
CCTG-PR26

Clinical Trial Categories

  • Breast Cancer
Contact
Clinical Trials at 910-715-2200
How to Participate

Eligibility: Men 18+ years old, with diagnosis of adenocarcinoma of the prostate, must have received androgen deprivation therapy for at least 6 months and no more than 12 months, must have received androgen receptor pathway inhibitor for at least 4 months, and has experienced disease progression. 

Contact Us

For more information on participating in a clinical trial, contact us at 910-715-2200 or talk to your doctor.